Incidence of Peripheral Neuropathy with Docetaxel versus Paclitaxel in Women Treated for Breast Cancer (P6.172)

Conclusions:The incidence but not severity of CIPN is significantly higher in women treated with paclitaxel when compared to docetaxel. Fully understanding the differences in the development of CIPN between the taxanes is crucial for making treatment decisions and managing patients with breast cancer.Disclosure: Dr. Karafiath has nothing to disclose. Dr. Kolb has nothing to disclose. Dr. Singleton has nothing to disclose. Dr. Smith has received personal compensation for activities with CSL Behring, Grifols, and Allergan as a consultant. Dr. Smith has received personal compensation in an editorial capacity for NeuroLearn. Dr. Smith has received research support from the NIH, the ADA, and Impeto.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Karafiath, S., Kolb, N., Singleton, J., Smith, A. G. Tags: Neurologic Complications of Cancer Source Type: research